遺伝子治療市場：ベクタータイプ別、治療様式別、標的ゲノム別、送達様式別、投与経路別、患者タイプ別、治療領域別、エンドユーザー別-2025-2030年世界予測

遺伝子治療市場は、2023年に82億9,000万米ドルと評価され、2024年には103億1,000万米ドル、CAGR27.15%で成長し、2030年には446億1,000万米ドルに達すると予測されています。

遺伝子治療は、理論上の可能性から複雑な疾患の治療における実用的な礎石へと急速に昇華しました。ゲノム編集、ベクター開発、治療戦略の進化が進み、かつて不治の病とされた疾患の治療に前例のない道が開かれました。この絶え間ない技術革新の環境の中で、企業は遺伝子治療の可能性を活用し、遺伝子の異常を直接ターゲットとしています。公共投資と民間投資の両輪による広範な調査が、市場承認と世界的普及への道を形成しています。

本レポートでは、遺伝子治療業界の現状を総括するとともに、業界情勢を形成し続ける主要動向、技術的ブレークスルー、規制状況について論じています。臨床的成功、課題、将来の方向性の明確化に重点を置いています。市場力学と新たなパターンを徹底的に調査することで、科学的厳密さと思いやりのあるケアが出会う変革の説得力ある物語が明らかになります。最先端のバイオテクノロジーと確かな臨床データの統合は、遺伝子治療の変革の可能性を強調し、読者を個別化医療が標準となる未来へと誘う。

このような背景から、研究者から意思決定者までの利害関係者は、従来の戦略を再評価するよう促されています。本書は、遺伝子治療のブレークスルーを促進するマクロ動向と細部にわたる詳細の両方を明確にするため、慎重に構成されています。ここに掲載された包括的な分析を読み進めるうちに、この分野の急速な発展を支える技術革新、規制、市場力学の相互作用についての洞察が得られると思われます。

遺伝子治療市場の変革

遺伝子治療分野は、ヘルスケア提供のパラダイムを再定義する変革的なシフトを経験してきました。CRISPRのような遺伝子編集技術の進歩は、研究者が遺伝性疾患を修正するペースを加速させ、従来の治療が失敗したところに希望をもたらしています。この分野の急速な発展は、学術的な進歩と産業界の投資との共生関係によって推進されており、医学的に可能なことの限界を常に押し広げています。

特筆すべき進化は、従来の治療から、より的を絞った遺伝子介入への移行に起因します。様々な用途における臨床試験が、患者の転帰を改善するという説得力のある証拠を提供し、精密医療への再注目を煽っています。この転換は、臨床プロトコルを変えるだけでなく、革新的な治療法を受け入れるための規制状況の再評価をも必要としています。その結果、規制当局は、患者への迅速なアクセスと厳格な安全性評価の両方を確保するためのプロセスの適応をますます進めています。

さらに、バイオテクノロジーとデータ解析や人工知能の融合により、有望な治療薬候補の効率的な発見が可能になりました。このような統合的なアプローチは、医薬品開発に関連する時間とコストを削減し、研究室での画期的な発見から臨床への道のりを加速させるのに役立っています。遺伝子治療が注目を集め続ける中、市場参入企業は研究の優先順位を再調整し、治療介入の有効性と安全性をさらに高める次世代技術に投資することで、こうした進歩の恩恵を享受しています。

遺伝子治療市場の主要セグメンテーション洞察

遺伝子治療市場を詳細に分析すると、技術的・治療的応用の多様性を包含する、微妙なセグメンテーション戦略の重要性が浮き彫りになります。ベクターの種類に基づくセグメンテーションにより、非ウイルス性ベクターとウイルス性ベクターの二極化が明らかになりました。非ウイルス性ベクターの領域では、リポフェクションやプラスミドDNAのような送達メカニズムが、その使いやすさと比較的単純な製造工程により支持を得ています。一方、アデノ随伴ウイルス（AAV）、アデノウイルス、単純ヘルペスウイルス（HSV）、レトロウイルスベクターなどのウイルスベクターは、より高い導入効率と持続的な遺伝子発現を提供し、慢性疾患にとって魅力的です。

治療法を考える場合、生殖細胞治療と体細胞治療の区別が重要になります。生殖細胞治療は、根本的なレベルで遺伝子の誤りを修正する可能性があるが、依然として議論の余地があり、規制も厳しいです。これとは対照的に、体細胞療法は、主に遺伝子増強と遺伝子抑制技術に焦点を当てたもので、比較的リスクが低く、臨床応用がより容易であることから、勢いを増し続けています。これらの手法では、遺伝的な遺伝子構成を変えることなく、疾患の根本的な原因をターゲットとした改変が可能です。

さらに細分化された洞察は、標的ゲノムの改変にも及び、そこではDNA改変とRNA改変の間に焦点が移っています。例えば、RNA技術における革新は、ウイルス感染や代謝異常などの病態に迅速に対処する上で極めて重要であることが証明されつつあるが、一方で、従来のDNA改変技術は、長期的な治療解決策には依然として不可欠です。さらに、送達様式と投与経路による分類が、市場情勢をさらに洗練させています。生体外および生体内の送達システムは、筋肉内、眼内、静脈内といった投与経路とともに批判的に評価されており、それぞれが有効性と患者のコンプライアンスという点で明確な利点を提供しています。

さらに、患者タイプや治療分野に基づくセグメンテーションにより、市場需要の包括的な概観が得られます。成人患者集団と小児患者集団を区別することで、的を絞った治療戦略が可能になり、また、心血管疾患、感染症、単発性疾患、腫瘍性疾患にまたがる治療分野では、特定の臨床課題が概説されます。例えば、心血管疾患を冠動脈疾患と心不全に分類することで、個々の患者に合わせた遺伝子治療が必要とされることがわかる。感染症にも同様の粒度が適用され、B型肝炎とHIVが市場の大きな注目を集めています。嚢胞性線維症から血友病、鎌状赤血球貧血に至る単発性疾患の分析では、精密治療に対する重要なニーズが浮き彫りにされ、一方、腫瘍性疾患は血液悪性腫瘍と固形腫瘍に分類され、それぞれオーダーメイドの治療法が求められています。

最後に、受託研究機関、病院・診療所、製薬・バイオテクノロジー企業、研究機関などのエンドユーザーに基づくセグメンテーションは、遺伝子治療開発と商業化のダイナミックな状況を反映しています。この多角的なセグメンテーションアプローチは、市場動向のより深い理解をサポートし、利害関係者が目標とする治療法、人口統計学的、技術的基準に基づいて洗練された戦略を展開することを可能にします。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で遺伝性疾患や希少疾患の罹患率が上昇していることから、遺伝子治療の需要が高まっています。
    • 臨床試験を支援する公的および民間の資金提供イニシアチブの増加
    • 革新的な遺伝子治療の承認プロセスを加速する規制枠組みの改善
  • 抑制要因
    • 遺伝子治療治療に伴う高額な費用
  • 機会
    • AIと機械学習を活用して遺伝子治療の研究開発プロセスを効率化
    • CRISPRやその他の遺伝子編集技術における継続的な革新
  • 課題
    • 遺伝子治療に関連する運用上の懸念事項
• 市場セグメンテーション分析
  • ベクタータイプ：眼疾患および神経疾患におけるアデノ随伴ウイルスの顕著な採用
  • 治療法：より安全なプロファイルと規制上の容認性により、体細胞療法が大きく普及している
  • ターゲットゲノム：より迅速な制御プロトコルによるRNA修飾の影響の急速な拡大
  • 送達モード：非制限的な適用を特徴とする生体内送達の好ましさが高まっている
  • 投与経路：広範囲の遺伝性疾患に適した静脈内投与の使用が拡大している
  • 患者のタイプ：成人発症の遺伝性疾患の発生率が高いため、成人患者における遺伝子治療の利用が増加している
  • 治療領域：感染症の蔓延により強力な遺伝子治療が必要
  • エンドユーザー：遺伝子治療イノベーションにおける製薬企業とバイオテクノロジー企業の重要性の拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 遺伝子治療市場ベクトルタイプ別

• 非ウイルスベクター
  • リポフェクション
  • プラスミドDNA
• ウイルスベクター
  • アデノ随伴ウイルス（AAV）ベクター
  • アデノウイルスベクター
  • 単純ヘルペスウイルス（HSV）ベクター
  • レトロウイルスベクター

第7章 遺伝子治療市場治療法別

• 生殖細胞療法
• 体細胞療法
  • 遺伝子増強療法
  • 遺伝子抑制療法

第8章 遺伝子治療市場ターゲットゲノム

• DNA修飾
• RNA修飾

第9章 遺伝子治療市場配送方法別

• 生体外
• In vivo

第10章 遺伝子治療市場：投与経路別

• 筋肉内
• 眼内
• 静脈内

第11章 遺伝子治療市場患者タイプ別

• 成人患者
• 小児患者

第12章 遺伝子治療市場治療領域別

• 心血管疾患
  • 冠動脈疾患
  • 心不全
• 感染症
  • B型肝炎
  • HIV
• 単一遺伝子疾患
  • 嚢胞性線維症
  • 血友病
  • 鎌状赤血球貧血
• 腫瘍性疾患
  • 造血悪性腫瘍
  • 固形腫瘍

第13章 遺伝子治療市場：エンドユーザー別

• 契約調査機関
• 病院と診療所
• 製薬・バイオテクノロジー企業
• 調査機関

第14章 南北アメリカの遺伝子治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第15章 アジア太平洋地域の遺伝子治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第16章 欧州・中東・アフリカの遺伝子治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第17章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abeona Therapeutics Inc.
• Adaptimmune Therapeutics PLC
• Adverum Biotechnologies, Inc.
• AGC Biologics
• Alnylam Pharmaceuticals, Inc.
• American Gene Technologies Inc.
• Amgen Inc.
• AnGes, Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• bluebird bio, Inc.
• Cellectis S.A.
• CRISPR Therapeutics AG
• Danaher Corporation
• Editas Medicine, Inc.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Intellia Therapeutics
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Merck KGaA
• Mustang Bio, Inc.
• Novartis AG
• Orchard Therapeutics PLC
• Poseida Therapeutics, Inc.
• Sangamo Therapeutics, Inc.
• Sarepta Therapeutics, Inc.
• Sibiono GeneTech Co. Ltd.
• Syncona Limited
• ViGeneron GmbH
• Voyager Therapeutics Inc.

LIST OF FIGURES

• FIGURE 1. GENE THERAPY MARKET MULTI-CURRENCY
• FIGURE 2. GENE THERAPY MARKET MULTI-LANGUAGE
• FIGURE 3. GENE THERAPY MARKET RESEARCH PROCESS
• FIGURE 4. GENE THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 21. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 23. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 27. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 29. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 30. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 31. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 32. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 33. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GENE THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 70. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 71. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 72. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 73. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 74. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 76. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 77. ARGENTINA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 78. ARGENTINA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 79. ARGENTINA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 80. ARGENTINA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 81. ARGENTINA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 82. ARGENTINA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 83. ARGENTINA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. ARGENTINA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. ARGENTINA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 86. ARGENTINA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 87. ARGENTINA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 88. ARGENTINA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 89. ARGENTINA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 90. ARGENTINA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 92. BRAZIL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 93. BRAZIL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 94. BRAZIL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 95. BRAZIL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 96. BRAZIL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 97. BRAZIL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 98. BRAZIL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. BRAZIL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. BRAZIL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 101. BRAZIL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 102. BRAZIL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 103. BRAZIL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 104. BRAZIL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 105. BRAZIL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 107. CANADA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 108. CANADA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 109. CANADA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 110. CANADA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. CANADA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 112. CANADA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 113. CANADA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. CANADA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. CANADA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 116. CANADA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 117. CANADA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 118. CANADA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 119. CANADA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 120. CANADA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 122. MEXICO GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 123. MEXICO GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 124. MEXICO GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 125. MEXICO GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 126. MEXICO GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 127. MEXICO GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 128. MEXICO GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. MEXICO GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 130. MEXICO GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 131. MEXICO GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 132. MEXICO GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 133. MEXICO GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 134. MEXICO GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 135. MEXICO GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 137. UNITED STATES GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 138. UNITED STATES GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 139. UNITED STATES GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 140. UNITED STATES GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 141. UNITED STATES GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 142. UNITED STATES GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED STATES GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED STATES GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED STATES GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 146. UNITED STATES GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 147. UNITED STATES GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 148. UNITED STATES GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 149. UNITED STATES GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 150. UNITED STATES GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 152. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 154. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 156. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 157. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 158. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 159. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 162. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 163. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 164. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 165. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 166. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 168. AUSTRALIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 169. AUSTRALIA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 170. AUSTRALIA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 171. AUSTRALIA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 172. AUSTRALIA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 173. AUSTRALIA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 174. AUSTRALIA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 175. AUSTRALIA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. AUSTRALIA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. AUSTRALIA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 178. AUSTRALIA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 179. AUSTRALIA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 180. AUSTRALIA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 181. AUSTRALIA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 182. AUSTRALIA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 184. CHINA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 185. CHINA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 186. CHINA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 187. CHINA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 188. CHINA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 189. CHINA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 190. CHINA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. CHINA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. CHINA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 193. CHINA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 194. CHINA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 195. CHINA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 196. CHINA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 197. CHINA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. INDIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 199. INDIA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 200. INDIA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 201. INDIA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 202. INDIA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 203. INDIA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 204. INDIA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 205. INDIA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. INDIA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 207. INDIA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 208. INDIA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 209. INDIA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 210. INDIA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 211. INDIA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 212. INDIA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. INDONESIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 214. INDONESIA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 215. INDONESIA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 216. INDONESIA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 217. INDONESIA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 218. INDONESIA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 219. INDONESIA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 220. INDONESIA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. INDONESIA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 222. INDONESIA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 223. INDONESIA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 224. INDONESIA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 225. INDONESIA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 226. INDONESIA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 227. INDONESIA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 229. JAPAN GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 230. JAPAN GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 231. JAPAN GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 232. JAPAN GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 233. JAPAN GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 234. JAPAN GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 235. JAPAN GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. JAPAN GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. JAPAN GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 238. JAPAN GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 239. JAPAN GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 240. JAPAN GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 241. JAPAN GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 242. JAPAN GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. MALAYSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 244. MALAYSIA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 245. MALAYSIA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 246. MALAYSIA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 247. MALAYSIA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 248. MALAYSIA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 249. MALAYSIA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 250. MALAYSIA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 251. MALAYSIA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 252. MALAYSIA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 253. MALAYSIA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 254. MALAYSIA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 255. MALAYSIA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 256. MALAYSIA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 257. MALAYSIA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 258. PHILIPPINES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 259. PHILIPPINES GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 260. PHILIPPINES GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 261. PHILIPPINES GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 262. PHILIPPINES GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 263. PHILIPPINES GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 264. PHILIPPINES GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 265. PHILIPPINES GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 266. PHILIPPINES GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 267. PHILIPPINES GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 268. PHILIPPINES GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 269. PHILIPPINES GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 270. PHILIPPINES GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 271. PHILIPPINES GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 272. PHILIPPINES GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. SINGAPORE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 274. SINGAPORE GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 275. SINGAPORE GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 276. SINGAPORE GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 277. SINGAPORE GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 278. SINGAPORE GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 279. SINGAPORE GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 280. SINGAPORE GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. SINGAPORE GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 282. SINGAPORE GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 283. SINGAPORE GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 284. SINGAPORE GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 285. SINGAPORE GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 286. SINGAPORE GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 287. SINGAPORE GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 288. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 289. SOUTH KOREA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 290. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 291. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 292. SOUTH KOREA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 293. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 294. SOUTH KOREA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 295. SOUTH KOREA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 296. SOUTH KOREA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 297. SOUTH KOREA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 298. SOUTH KOREA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 299. SOUTH KOREA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 300. SOUTH KOREA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 301. SOUTH KOREA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 302. SOUTH KOREA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 303. TAIWAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 304. TAIWAN GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 305. TAIWAN GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 306. TAIWAN GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 307. TAIWAN GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 308. TAIWAN GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 309. TAIWAN GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 310. TAIWAN GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 311. TAIWAN GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 312. TAIWAN GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 313. TAIWAN GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 314. TAIWAN GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 315. TAIWAN GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 316. TAIWAN GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 317. TAIWAN GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 318. THAILAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 319. THAILAND GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 320. THAILAND GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 321. THAILAND GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 322. THAILAND GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 323. THAILAND GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 324. THAILAND GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 325. THAILAND GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 326. THAILAND GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 327. THAILAND GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 328. THAILAND GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 329. THAILAND GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 330. THAILAND GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 331. THAILAND GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 332. THAILAND GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 333. VIETNAM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 334. VIETNAM GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 335. VIETNAM GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 336. VIETNAM GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 337. VIETNAM GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 338. VIETNAM GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 339. VIETNAM GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 340. VIETNAM GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 341. VIETNAM GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 342. VIETNAM GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 343. VIETNAM GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 344. VIETNAM GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 345. VIETNAM GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 346. VIETNAM GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 347. VIETNAM GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 348. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
• TABLE 349. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 350. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 351. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 352. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 353. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2030 (USD MILLION)
• TABLE 354. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
• TABLE 355. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 356. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2

The Gene Therapy Market was valued at USD 8.29 billion in 2023 and is projected to grow to USD 10.31 billion in 2024, with a CAGR of 27.15%, reaching USD 44.61 billion by 2030.

Gene therapy has rapidly ascended from a theoretical possibility to a practical cornerstone in the treatment of complex diseases. The ongoing evolution in genomic editing, vector development, and therapeutic strategies has opened unprecedented avenues in treating conditions once deemed incurable. In this environment of relentless innovation, companies harness the potential of gene therapy to target genetic anomalies directly. Extensive research, fueled by both public and private investment, is shaping the path to market approval and global adoption.

This report encapsulates the current state of the gene therapy industry while discussing key trends, technological breakthroughs, and regulatory frameworks that continue to reshape the landscape. Emphasis is placed on the delineation of clinical successes, challenges, and future directions. A thorough exploration of the market dynamics and emerging patterns reveals a compelling narrative of transformation, where scientific rigor meets compassionate care. The integration of advanced biotechnologies with robust clinical data underscores the transformative potential of gene therapy and invites the reader to envision a future where personalized medicine becomes the norm.

Against this backdrop, stakeholders ranging from researchers to decision-makers are encouraged to re-evaluate conventional strategies. The discussion is carefully structured to provide clarity on both the macro trends and fine-grained details that drive breakthroughs in gene therapy. As you navigate through the comprehensive analysis presented here, you will gain insights into the interplay of innovation, regulation, and market dynamics that underpin the sector's rapid progression.

Transformative Shifts in the Gene Therapy Landscape

The gene therapy sector has experienced transformative shifts that redefine the paradigms of healthcare delivery. Advancements in gene editing technologies such as CRISPR have accelerated the pace at which researchers can correct genetic disorders, offering hope where traditional treatments have failed. The rapid development in this field is driven by a symbiotic relationship between academic advancements and industrial investments, consistently pushing the boundaries of what is medically possible.

A notable evolution stems from the transition from conventional treatments to more targeted genetic interventions. Clinical trials across various applications have provided compelling evidence of improved patient outcomes, fueling a renewed focus on precision medicine. This shift is not only changing clinical protocols, but it also necessitates a reassessment of the regulatory landscape to accommodate innovative therapeutic methods. Consequently, regulatory agencies are increasingly adapting processes to ensure both rapid patient access and rigorous safety evaluations.

Moreover, the convergence of biotechnology with data analytics and artificial intelligence has enabled the efficient discovery of promising therapeutic candidates. This integrated approach is instrumental in reducing the time and cost associated with drug development, thus accelerating the journey from laboratory breakthroughs to clinical reality. As gene therapy continues to garner attention, market participants are reaping the benefits of these advancements by realigning their research priorities and investing in next-generation technologies that further enhance the efficacy and safety of therapeutic interventions.

Key Segmentation Insights in Gene Therapy Markets

A detailed analysis of the gene therapy market underscores the importance of a nuanced segmentation strategy that encapsulates the diversity of technological and therapeutic applications. The segmentation based on vector type reveals a bifurcation between non-viral and viral vectors. Within the realm of non-viral vectors, delivery mechanisms such as lipofection and plasmid DNA have gained traction due to their ease of use and comparatively simple production processes. Meanwhile, viral vectors, including adeno-associated virus (AAV), adenovirus, herpes simplex virus (HSV), and retrovirus vectors, offer higher transduction efficiencies and sustained gene expression, making them attractive for chronic conditions.

When considering treatment modality, the distinction between germline therapy and somatic cell therapy becomes crucial. Germline therapy, which has the potential to correct genetic errors at a fundamental level, remains controversial and heavily regulated. In contrast, somatic cell therapy, primarily focused on gene augmentation and gene suppression techniques, continues to gain momentum due to its relatively lower risk profile and more straightforward clinical applications. These methodologies allow for modifications that target the underlying cause of disease without altering the hereditary genetic makeup.

Further segmentation insights extend to target genome modifications, where the focus shifts between DNA and RNA modifications. Innovations in RNA technology, for instance, are proving pivotal in rapidly addressing conditions such as viral infections and metabolic disorders, while traditional DNA modification techniques remain essential for long-term therapeutic solutions. Additional layers of categorization through delivery mode and route of administration further refine the market landscape. Ex vivo and in vivo delivery systems are critically evaluated alongside administration routes such as intramuscular, intraocular, and intravenous methods, each offering distinct advantages in terms of efficacy and patient compliance.

Additional segmentation based on patient type and therapeutic area provides a comprehensive overview of market demand. Differentiating between adult and pediatric patient populations ensures targeted treatment strategies, while therapeutic segments spanning cardiovascular diseases, infectious diseases, monogenic disorders, and oncological conditions outline specific clinical challenges. The classification of cardiovascular conditions into coronary artery disease and heart failure, for example, highlights the specific demand for tailored gene therapy interventions. Similar granularity is applied to infectious conditions, with hepatitis B and HIV capturing significant market attention. The analysis of monogenic disorders-ranging from cystic fibrosis to hemophilia and sickle cell anemia-underscores the critical need for precision therapies, whereas oncological disorders are dissected into hematological malignancies and solid tumors, each demanding bespoke treatment modalities.

Finally, segmentation based on end-users, including contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes, reflects the dynamic landscape of gene therapy development and commercialization. This multi-dimensional segmentation approach supports a deeper understanding of market trends, enabling stakeholders to deploy refined strategies based on targeted therapeutic, demographic, and technological criteria.

Based on Vector Type, market is studied across Non-Viral Vectors and Viral Vectors. The Non-Viral Vectors is further studied across Lipofection and Plasmid DNA. The Viral Vectors is further studied across Adeno-Associated Virus (AAV) Vectors, Adenovirus Vectors, Herpes Simplex Virus (HSV) Vectors, and Retrovirus Vectors.

Based on Treatment Modality, market is studied across Germline Therapy and Somatic Cell Therapy. The Somatic Cell Therapy is further studied across Gene Augmentation Therapy and Gene Suppression Therapy.

Based on Target Genome, market is studied across DNA Modification and RNA Modification.

Based on Delivery Mode, market is studied across Ex Vivo and In Vivo.

Based on Route of Administration, market is studied across Intramuscular, Intraocular, and Intravenous.

Based on Patient Type, market is studied across Adult Patients and Pediatric Patients.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Monogenic Disorders, and Oncological Disorders. The Cardiovascular Diseases is further studied across Coronary Artery Disease and Heart Failure. The Infectious Diseases is further studied across Hepatitis B and HIV. The Monogenic Disorders is further studied across Cystic Fibrosis, Hemophilia, and Sickle Cell Anemia. The Oncological Disorders is further studied across Hematological Malignancies and Solid Tumors.

Based on End-User, market is studied across Contract Research Organizations, Hospitals & Clinics, Pharmaceutical & Biotech Companies, and Research Institutes.

Key Regional Insights Shaping Global Gene Therapy Markets

Regional dynamics play a pivotal role in the evolution of the gene therapy market. The Americas have emerged as a dominant region where innovation and robust clinical pipelines drive significant market value. Collaborative efforts between regulatory bodies, academic institutions, and biotech companies have fostered a conducive environment for advanced clinical trials and accelerated product approvals. This progress underscores the region's commitment to integrating breakthrough therapies into mainstream healthcare.

Europe, the Middle East, and Africa bring a diverse set of regulatory frameworks and market maturities, which translate into a region characterized by both high innovation intensity and localized challenges. The region boasts world-class research facilities and a rich history of biomedical breakthroughs, thereby acting as a fertile ground for the translation of gene therapy from bench to bedside. Strategic collaborations and harmonized regulatory initiatives have been instrumental in bolstering market acceptance and patient access in these territories.

The Asia-Pacific region, with its rapidly growing economies and expanding healthcare infrastructure, offers fertile ground for future gene therapy advancements. Increasing investments in pharmaceutical R&D and technology adoption are accelerating the implementation of gene therapies, especially in countries where rising disposable incomes and enhanced healthcare systems are driving demand. As these regions continue to mature, they are likely to become significant contributors to the global gene therapy market, underscoring the importance of tailoring strategies to diverse regulatory and socio-economic environments.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Setting the Pace in Gene Therapy Innovation

The competitive landscape in gene therapy is punctuated by a range of visionary companies that are pushing the boundaries of medical science. Innovators like Abeona Therapeutics Inc. and Adaptimmune Therapeutics PLC are rapidly advancing novel therapeutic platforms that promise to redefine patient outcomes. Other industry pioneers, such as Adverum Biotechnologies, Inc. and AGC Biologics, focus on optimizing vector delivery systems and scalable manufacturing processes, accentuating the operational prowess required for market success.

Major players are also leveraging rich pipelines and strategic partnerships to build resilient portfolios focused on rare and common genetic disorders alike. Esteemed organizations including Alnylam Pharmaceuticals, Inc. and American Gene Technologies Inc. continue to invest in robust R&D activities, while Amgen Inc. and AnGes, Inc. harness state-of-the-art biotechnologies to enhance the safety and specificity of gene therapies. The likes of Astellas Pharma Inc. and Biogen Inc. are setting benchmarks in clinical innovation, further amplified by the disruptive potential of bluebird bio, Inc. and Cellectis S.A.

Companies such as CRISPR Therapeutics AG and Editas Medicine, Inc. are leading the charge in precision genome editing technologies, attracting keen investor interest and regulatory support alike. Larger conglomerates like Danaher Corporation and F. Hoffmann-La Roche Ltd. bring pharmaceutical might and expansive market reach, while industry stalwarts including Gilead Sciences, Inc. and Intellia Therapeutics refine the scientific rigour behind clinical trial designs. Ionis Pharmaceuticals, Inc., along with Johnson & Johnson and Merck KGaA, continues to expand their therapeutic horizons by integrating gene therapies into broader treatment regimens. Storied innovators like Mustang Bio, Inc. and Novartis AG are demonstrating remarkable agility in navigating the complex interplay of clinical innovation and commercial viability. The strategic visions of Orchard Therapeutics PLC, Poseida Therapeutics, Inc., and Sangamo Therapeutics, Inc. further illuminate pathways to market integration, with Sarepta Therapeutics, Inc., Sibiono GeneTech Co. Ltd., Syncona Limited, ViGeneron GmbH, and Voyager Therapeutics Inc. rounding out a comprehensive tapestry of industry excellence.

The report delves into recent significant developments in the Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, Adverum Biotechnologies, Inc., AGC Biologics, Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Astellas Pharma Inc., Biogen Inc., bluebird bio, Inc., Cellectis S.A., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Intellia Therapeutics, Ionis Pharmaceuticals, Inc., Johnson & Johnson, Merck KGaA, Mustang Bio, Inc., Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Sibiono GeneTech Co. Ltd., Syncona Limited, ViGeneron GmbH, and Voyager Therapeutics Inc.. Actionable Recommendations for Industry Leaders

Industry leaders should focus on leveraging cutting-edge research and consolidating robust partnerships to accelerate market penetration. It is crucial to invest in scalable manufacturing processes that accommodate sophisticated vector development while ensuring quality control and compliance with evolving regulatory standards. Emphasis must be placed on establishing dynamic clinical trial frameworks that are adaptive to emerging scientific data and patient feedback, thereby shortening the timeline from discovery to approval.

Additionally, aligning with strategic innovation clusters and research consortiums can provide valuable insights into regional market dynamics and advanced technological trends. Leaders should also consider diversifying their pipelines by strategically targeting both prevalent and niche therapeutic areas, enabling a balanced portfolio that mitigates market risks. Embedding advanced digital analytics into every phase of the development process can facilitate data-driven decision making, ensuring that product lifecycles are optimized for both clinical efficacy and cost efficiency.

Finally, a proactive engagement with regulatory bodies and industry stakeholders is essential to anticipate shifts in policy and technological landscapes. By staying ahead of the curve through continual investment in innovation and fostering collaborative synergies, industry leaders can drive sustained growth and establish enduring competitive advantages in the gene therapy arena.

Conclusion: Embracing the Future of Transformative Therapeutics

In summary, the gene therapy market is positioned at the intersection of groundbreaking science and evolving clinical realities. The transformative shifts in technological innovation, regulatory modernization, and proactive industry collaboration signal a paradigm where precision medicine can truly revolutionize patient care. By embracing detailed segmentation insights, regional trends, and the diverse strategies of key industry players, stakeholders are equipped to navigate the complexities inherent in this ever-changing landscape.

A clear focus on patient-centric innovation, combined with strategic investments in technology and infrastructure, reaffirms a future where genetic anomalies can be addressed with unprecedented precision and efficacy. The collective momentum of the industry encapsulates a vision for a healthier, more resilient future where gene therapy is integral to mainstream medical practice.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for gene therapy driven by rising prevalence of genetic and rare diseases worldwide
    • 5.1.1.2. Growing public and private funding initiatives supporting gene therapy clinical trials
    • 5.1.1.3. Improved regulatory frameworks accelerating the approval process for innovative gene therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with the gene therapy treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Leveraging AI and machine learning to streamline gene therapy research and development processes
    • 5.1.3.2. Ongoing innovations in CRISPR and other gene-editing technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Operational concerns associated with the gene therapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Vector Type: Significant adoption of adeno-associated viruses in ocular and neurological disorders
  • 5.2.2. Treatment Modality: Substantial traction of somatic cell therapy, driven by safer profiles and regulatory acceptability
  • 5.2.3. Target Genome: Burgeoning influence of RNA modification owing to their faster regulatory protocols
  • 5.2.4. Delivery Mode: Growing preference for in vivo delivery characterized by its non-restrictive application
  • 5.2.5. Route of Administration: Proliferating usage of the intravenous administration suitable for a broad spectrum of genetic disorders
  • 5.2.6. Patient Type: Increasing utilization of gene therapies among adult patients owing to the higher incidence of adult-onset genetic disorders
  • 5.2.7. Therapeutic Area: Rising prevalence of infectious diseases demands robust gene therapies
  • 5.2.8. End-User: Expanding importance of the pharmaceutical and biotech companies for gene therapy innovations
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gene Therapy Market, by Vector Type

• 6.1. Introduction
• 6.2. Non-Viral Vectors
  • 6.2.1. Lipofection
  • 6.2.2. Plasmid DNA
• 6.3. Viral Vectors
  • 6.3.1. Adeno-Associated Virus (AAV) Vectors
  • 6.3.2. Adenovirus Vectors
  • 6.3.3. Herpes Simplex Virus (HSV) Vectors
  • 6.3.4. Retrovirus Vectors

7. Gene Therapy Market, by Treatment Modality

• 7.1. Introduction
• 7.2. Germline Therapy
• 7.3. Somatic Cell Therapy
  • 7.3.1. Gene Augmentation Therapy
  • 7.3.2. Gene Suppression Therapy

8. Gene Therapy Market, by Target Genome

• 8.1. Introduction
• 8.2. DNA Modification
• 8.3. RNA Modification

9. Gene Therapy Market, by Delivery Mode

• 9.1. Introduction
• 9.2. Ex Vivo
• 9.3. In Vivo

10. Gene Therapy Market, by Route of Administration

• 10.1. Introduction
• 10.2. Intramuscular
• 10.3. Intraocular
• 10.4. Intravenous

11. Gene Therapy Market, by Patient Type

• 11.1. Introduction
• 11.2. Adult Patients
• 11.3. Pediatric Patients

12. Gene Therapy Market, by Therapeutic Area

• 12.1. Introduction
• 12.2. Cardiovascular Diseases
  • 12.2.1. Coronary Artery Disease
  • 12.2.2. Heart Failure
• 12.3. Infectious Diseases
  • 12.3.1. Hepatitis B
  • 12.3.2. HIV
• 12.4. Monogenic Disorders
  • 12.4.1. Cystic Fibrosis
  • 12.4.2. Hemophilia
  • 12.4.3. Sickle Cell Anemia
• 12.5. Oncological Disorders
  • 12.5.1. Hematological Malignancies
  • 12.5.2. Solid Tumors

13. Gene Therapy Market, by End-User

• 13.1. Introduction
• 13.2. Contract Research Organizations
• 13.3. Hospitals & Clinics
• 13.4. Pharmaceutical & Biotech Companies
• 13.5. Research Institutes

14. Americas Gene Therapy Market

• 14.1. Introduction
• 14.2. Argentina
• 14.3. Brazil
• 14.4. Canada
• 14.5. Mexico
• 14.6. United States

15. Asia-Pacific Gene Therapy Market

• 15.1. Introduction
• 15.2. Australia
• 15.3. China
• 15.4. India
• 15.5. Indonesia
• 15.6. Japan
• 15.7. Malaysia
• 15.8. Philippines
• 15.9. Singapore
• 15.10. South Korea
• 15.11. Taiwan
• 15.12. Thailand
• 15.13. Vietnam

16. Europe, Middle East & Africa Gene Therapy Market

• 16.1. Introduction
• 16.2. Denmark
• 16.3. Egypt
• 16.4. Finland
• 16.5. France
• 16.6. Germany
• 16.7. Israel
• 16.8. Italy
• 16.9. Netherlands
• 16.10. Nigeria
• 16.11. Norway
• 16.12. Poland
• 16.13. Qatar
• 16.14. Russia
• 16.15. Saudi Arabia
• 16.16. South Africa
• 16.17. Spain
• 16.18. Sweden
• 16.19. Switzerland
• 16.20. Turkey
• 16.21. United Arab Emirates
• 16.22. United Kingdom

17. Competitive Landscape

• 17.1. Market Share Analysis, 2023
• 17.2. FPNV Positioning Matrix, 2023
• 17.3. Competitive Scenario Analysis
  • 17.3.1. Be Biopharma secures USD 82 million to propel innovative haemophilia B gene therapy into early trials
  • 17.3.2. Fiocruz and GEMMABio collaboration paves the way for affordable gene therapy solutions in Brazil
  • 17.3.3. An exclusive partnership between Astellas Pharma and AviadoBio transforms gene therapy landscape with AVB-101
  • 17.3.4. FDA clearance ushers in AAV vector-based immunotherapy VNX-101 for leukemia trials
  • 17.3.5. CPC launched MicroCNX ULT series for cell and gene therapy cryopreservation
  • 17.3.6. NHS pioneers global first with gene therapy Casgevy to transform thalassemia care
  • 17.3.7. Merck's acquisition of Mirus Bio signals strategic expansion in viral vector bioprocessing capabilities for advancing gene therapy solutions
  • 17.3.8. Pfizer's promising phase 3 trial outcomes highlight potential improvement in hemophilia A gene therapy
  • 17.3.9. Genezen strengthens its production capabilities with acquisition of uniQure's Massachusetts operations
  • 17.3.10. India revolutionizes cancer treatment with its first affordable indigenous CAR-T gene therapy, NexCAR19
  • 17.3.11. Kyowa Kirin expands rare disease gene therapy portfolio with dynamic acquisition of Orchard Therapeutics
  • 17.3.12. Novartis and Voyager Therapeutics partner to revolutionize gene therapy for genetic disorders
• 17.4. Strategy Analysis & Recommendation
  • 17.4.1. F. Hoffmann-La Roche Ltd.
  • 17.4.2. Novartis AG
  • 17.4.3. Biogen Inc.
  • 17.4.4. Astellas Pharma Inc.

Companies Mentioned

• 1. Abeona Therapeutics Inc.
• 2. Adaptimmune Therapeutics PLC
• 3. Adverum Biotechnologies, Inc.
• 4. AGC Biologics
• 5. Alnylam Pharmaceuticals, Inc.
• 6. American Gene Technologies Inc.
• 7. Amgen Inc.
• 8. AnGes, Inc.
• 9. Astellas Pharma Inc.
• 10. Biogen Inc.
• 11. bluebird bio, Inc.
• 12. Cellectis S.A.
• 13. CRISPR Therapeutics AG
• 14. Danaher Corporation
• 15. Editas Medicine, Inc.
• 16. F. Hoffmann-La Roche Ltd.
• 17. Gilead Sciences, Inc.
• 18. Intellia Therapeutics
• 19. Ionis Pharmaceuticals, Inc.
• 20. Johnson & Johnson
• 21. Merck KGaA
• 22. Mustang Bio, Inc.
• 23. Novartis AG
• 24. Orchard Therapeutics PLC
• 25. Poseida Therapeutics, Inc.
• 26. Sangamo Therapeutics, Inc.
• 27. Sarepta Therapeutics, Inc.
• 28. Sibiono GeneTech Co. Ltd.
• 29. Syncona Limited
• 30. ViGeneron GmbH
• 31. Voyager Therapeutics Inc.